UY33408A - ?agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes? - Google Patents

?agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes?

Info

Publication number
UY33408A
UY33408A UY33408A UY33408A UY33408A UY 33408 A UY33408 A UY 33408A UY 33408 A UY33408 A UY 33408A UY 33408 A UY33408 A UY 33408A UY 33408 A UY33408 A UY 33408A
Authority
UY
Uruguay
Prior art keywords
immune
cancer
treatment
autoimmune diseases
inductive agents
Prior art date
Application number
UY33408A
Other languages
English (en)
Inventor
Andrew J Souers
Zhi-Fu Tao
Wang Xilu
Nathaniel D Catron
Gerard M Sullivan
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45004346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY33408A publication Critical patent/UY33408A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos que inhiben la actividad de las proteínas anti-apoptóticas Bcl-2, composiciones que contienen dichos compuestos y métodos para tratar enfermedades durante las cuales se expresa la proteína anti-apoptótica Bcl-2.
UY33408A 2010-05-26 2011-05-25 ?agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes? UY33408A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34842210P 2010-05-26 2010-05-26

Publications (1)

Publication Number Publication Date
UY33408A true UY33408A (es) 2011-12-30

Family

ID=45004346

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33408A UY33408A (es) 2010-05-26 2011-05-25 ?agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes?

Country Status (39)

Country Link
US (5) US9006247B2 (es)
EP (3) EP2575463B1 (es)
JP (1) JP5782508B2 (es)
KR (2) KR101850679B1 (es)
CN (2) CN102939009B (es)
AR (1) AR081552A1 (es)
AU (1) AU2011258350B2 (es)
BR (1) BR112012029733B1 (es)
CA (1) CA2798765C (es)
CL (1) CL2012003285A1 (es)
CO (1) CO6640275A2 (es)
CR (2) CR20180222A (es)
CY (1) CY1117655T1 (es)
DK (1) DK2575463T3 (es)
DO (3) DOP2012000298A (es)
EC (1) ECSP12012348A (es)
ES (2) ES2574855T3 (es)
GT (1) GT201200315A (es)
HK (1) HK1182593A1 (es)
HR (1) HRP20160714T1 (es)
HU (1) HUE029231T2 (es)
IL (2) IL222831A (es)
ME (1) ME02452B (es)
MX (1) MX337104B (es)
MY (1) MY165427A (es)
NZ (1) NZ603284A (es)
PE (2) PE20170465A1 (es)
PH (2) PH12016501126A1 (es)
PL (1) PL2575463T3 (es)
PT (1) PT2575463T (es)
RS (1) RS54892B1 (es)
RU (1) RU2567857C2 (es)
SG (3) SG185447A1 (es)
SI (1) SI2575463T1 (es)
TW (1) TWI520960B (es)
UA (1) UA109278C2 (es)
UY (1) UY33408A (es)
WO (1) WO2011150016A1 (es)
ZA (1) ZA201208727B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
RU2598345C2 (ru) 2010-10-29 2016-09-20 Эббви Инк. Твердые дисперсии, содержащие средства, вызывающие апоптоз
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
JP2015502366A (ja) 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
ES2677480T3 (es) * 2012-08-13 2018-08-02 Abbvie Inc. Agentes que inducen apoptosis
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
CN111481552A (zh) 2012-09-07 2020-08-04 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
CA2903797C (en) * 2013-03-13 2022-06-21 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US9006438B2 (en) 2013-03-13 2015-04-14 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
CN106957315B (zh) * 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20170300968A1 (en) * 2016-04-14 2017-10-19 Nb Portals, Llc Method and system for disseminating information over a communication network
RS61821B1 (sr) * 2016-08-05 2021-06-30 Univ Michigan Regents Derivati n-(fenilsulfonil)benzamida kao bcl-2 inhibitori
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
WO2018157803A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
CN108794358B (zh) * 2017-04-27 2022-08-12 中国人民解放军第二军医大学 取代苯磺酰基类化合物及其制备药物的用途
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
CN107501260B (zh) * 2017-08-14 2019-08-13 郑州大学第一附属医院 一种Bcl-2抑制剂venetoclax以及中间体的制备方法
CN111448198B (zh) 2017-08-23 2023-02-03 广州麓鹏制药有限公司 作为治疗新生性疾病的Bcl-2抑制剂的缩合杂环衍生物
CN107445958A (zh) * 2017-09-19 2017-12-08 上海泓博智源医药股份有限公司 一种abt‑199中间体的制备方法
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
AU2019207611A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MX2020008569A (es) * 2018-02-16 2020-09-21 Abbvie Inc Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112020022092A2 (pt) 2018-04-29 2021-02-02 Beigene, Ltd. compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica
AU2019315466B2 (en) 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
US11491167B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
GEP20237458B (en) 2018-07-31 2023-01-10 Ascentage Pharma Suzhou Co Ltd Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN112661751B (zh) * 2019-10-16 2024-06-14 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN117377672A (zh) * 2021-06-04 2024-01-09 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
NZ585085A (en) 2007-11-16 2012-08-31 Abbott Lab Method of treating arthritis using arylsulfonamide compounds
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02642B (me) * 2008-12-05 2017-06-20 Abbvie Inc Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
ES2536090T3 (es) * 2009-01-19 2015-05-20 Abbvie Inc. Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias
PL2435432T6 (pl) 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
US20190315737A1 (en) 2019-10-17
SG10201700115RA (en) 2017-02-27
EP3091017A1 (en) 2016-11-09
KR101850679B1 (ko) 2018-04-20
CL2012003285A1 (es) 2013-10-04
DK2575463T3 (en) 2016-07-25
CA2798765C (en) 2018-10-23
CO6640275A2 (es) 2013-03-22
BR112012029733A2 (pt) 2017-06-13
CN102939009B (zh) 2015-03-25
AU2011258350A1 (en) 2012-11-22
IL222831A (en) 2014-08-31
US9403822B2 (en) 2016-08-02
EP3312178A1 (en) 2018-04-25
US9006247B2 (en) 2015-04-14
ME02452B (me) 2016-09-20
HK1182593A1 (zh) 2013-12-06
US20200277291A1 (en) 2020-09-03
US20170096424A1 (en) 2017-04-06
CY1117655T1 (el) 2017-05-17
PT2575463T (pt) 2016-07-13
PE20170465A1 (es) 2017-05-18
ZA201208727B (en) 2013-07-31
IL222831A0 (en) 2012-12-31
SG185447A1 (en) 2012-12-28
DOP2012000298A (es) 2018-04-30
ES2666181T3 (es) 2018-05-03
US20120028925A1 (en) 2012-02-02
RS54892B1 (sr) 2016-10-31
CN102939009A (zh) 2013-02-20
PH12018501264A1 (en) 2019-07-01
JP2013526612A (ja) 2013-06-24
RU2012156940A (ru) 2014-07-10
CA2798765A1 (en) 2011-12-01
EP3091017B1 (en) 2018-01-17
PL2575463T3 (pl) 2016-10-31
PH12016501126B1 (en) 2017-06-14
UA109278C2 (uk) 2015-08-10
CR20120648A (es) 2013-04-03
AR081552A1 (es) 2012-10-03
BR112012029733B1 (pt) 2020-12-01
CR20180222A (es) 2018-06-05
ES2574855T3 (es) 2016-06-22
TWI520960B (zh) 2016-02-11
KR20130086954A (ko) 2013-08-05
TW201141862A (en) 2011-12-01
AU2011258350B2 (en) 2015-04-09
US20150246914A1 (en) 2015-09-03
HUE029231T2 (en) 2017-02-28
PE20130221A1 (es) 2013-04-04
HRP20160714T1 (hr) 2016-07-15
EP2575463B1 (en) 2016-03-30
IL233832A0 (en) 2014-09-30
DOP2016000100A (es) 2016-05-31
PH12016501126A1 (en) 2017-06-14
SI2575463T1 (sl) 2016-11-30
ECSP12012348A (es) 2013-04-30
MX2012013704A (es) 2013-03-21
MY165427A (en) 2018-03-22
SG10201700112VA (en) 2017-03-30
KR101800167B1 (ko) 2017-11-22
IL233832B (en) 2018-05-31
RU2567857C2 (ru) 2015-11-10
EP2575463A4 (en) 2013-11-27
GT201200315A (es) 2014-07-11
CN104961771B (zh) 2018-02-02
DOP2017000186A (es) 2017-09-15
JP5782508B2 (ja) 2015-09-24
WO2011150016A1 (en) 2011-12-01
MX337104B (es) 2016-02-09
NZ603284A (en) 2015-01-30
KR20170083164A (ko) 2017-07-17
CN104961771A (zh) 2015-10-07
EP2575463A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
CR20120631A (es) Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
ECSP12012017A (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
CO6571908A2 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedaded inmunes y autoinmunes
CR20110351A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DOP2014000074A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200629